At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIVI BioVie Inc
Pre-Mkt 10-20 08:00:14 EDT
1.37
+0.17
+14.17%
盘前1.33
-0.04-2.92%
07:49 EDT
High1.39Low1.20Vol182.52K
Open1.29D1 Closing1.20Amplitude15.53%
Mkt Cap11.90MTradable Cap11.81MTotal Shares8.68M
T/O241.00KT/O Rate2.12%Tradable Shares8.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BioVie presents Phase 2 data on bezisterim in Long COVID
TIPRANKS  ·  10-19 21:20
BioVie presents Phase 2 data on bezisterim in Long COVID
BioVie’s Bezisterim Improves Fatigue in More Severely Affected Long COVID Patients in Phase 2 Trial
Reuters  ·  10-19 20:09
BioVie’s Bezisterim Improves Fatigue in More Severely Affected Long COVID Patients in Phase 2 Trial
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
GlobeNewswire  ·  10-19 20:00
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
BioVie to Present Phase 2 Bezisterim Long COVID Trial Results at ANA 2026 Meeting
Reuters  ·  10-14
BioVie to Present Phase 2 Bezisterim Long COVID Trial Results at ANA 2026 Meeting
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
GlobeNewswire  ·  10-14
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo
Reuters  ·  09-16
U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo
BioVie Falls After Long COVID Drug Fails to Show Benefit in Overall Trial
Reuters  ·  09-15
BioVie Falls After Long COVID Drug Fails to Show Benefit in Overall Trial
BioVie announces topline results from ADDRESS-LC trial
TIPRANKS  ·  09-15
BioVie announces topline results from ADDRESS-LC trial
BioVie Announces Topline Results from Phase 2 Address‑Lc Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid
THOMSON REUTERS  ·  09-15
BioVie Announces Topline Results from Phase 2 Address‑Lc Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid
BioVie - 41.6% of Bezisterim Patients Experienced Adverse Events vs 55.9% for Placebo
THOMSON REUTERS  ·  09-15
BioVie - 41.6% of Bezisterim Patients Experienced Adverse Events vs 55.9% for Placebo
BioVie - Bezisterim Safety and Tolerability Profile Similar to Placebo
THOMSON REUTERS  ·  09-15
BioVie - Bezisterim Safety and Tolerability Profile Similar to Placebo
BioVie - Bezisterim Shows Advantage over Placebo on 21 of 22 Endpoints in Phase 2 Trial
THOMSON REUTERS  ·  09-15
BioVie - Bezisterim Shows Advantage over Placebo on 21 of 22 Endpoints in Phase 2 Trial
NASDAQ Trade Halt Halt News Pending at 07:25 Am
Reuters  ·  09-15
NASDAQ Trade Halt Halt News Pending at 07:25 Am
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
GlobeNewswire  ·  09-15
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
BioVie Signs At-the-Market Equity Sales Agreement for up to $6.46 Million Class a Shares
Reuters  ·  09-14
BioVie Signs At-the-Market Equity Sales Agreement for up to $6.46 Million Class a Shares
BioVie Inc Files for Atm Offering of up to About $6.5 Mln Common Stock - SEC Filing
THOMSON REUTERS  ·  09-14
BioVie Inc Files for Atm Offering of up to About $6.5 Mln Common Stock - SEC Filing
Biovica Q1 FY27 Operating Loss Widens to SEK 20.33 Million; Net Sales Rise 56% to SEK 4.04 Million
Reuters  ·  09-10
Biovica Q1 FY27 Operating Loss Widens to SEK 20.33 Million; Net Sales Rise 56% to SEK 4.04 Million
BioVie Seeks FDA End-of-Phase 2 Meeting to Advance Bezisterim Phase 3 Parkinson’s Trial Design
Reuters  ·  09-08
BioVie Seeks FDA End-of-Phase 2 Meeting to Advance Bezisterim Phase 3 Parkinson’s Trial Design
BioVie Announces Update to Parkinson’s Phase 3 Development Program
THOMSON REUTERS  ·  09-08
BioVie Announces Update to Parkinson’s Phase 3 Development Program
BioVie - Requests End-of-Phase 2 Meeting with FDA, Expects Feedback Before Year-End
THOMSON REUTERS  ·  09-08
BioVie - Requests End-of-Phase 2 Meeting with FDA, Expects Feedback Before Year-End

Introduction

Company Name.
BioVie Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Issue price:
--